Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01857895 · ClinicalTrials.gov registry record · Phase 1
Feasibility Study of Exenatide by Continuous Subcutaneous Infusion
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01857895 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 10 participants.
The verdict
NCT01857895, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open-label study to investigate the feasibility of administering exenatide by continuous subcutaneous infusion to healthy subjects. Study will consist of two parts i.e. Part A and B. In Part A 2 healthy subjects will receive exenatide infusion over 24 hours followed by a follow-up visit 10 to 14 days after discharge from clinic. In Part B approximately 6 healthy subjects will receive subcutaneous infusions of exenatide for maximum of 7 days followed by a follow-up visit 10 to 14 days after discharge from clinic.
Interventions
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-05-16 |
| Est. Completion | 2013-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01857895
The ClinicalTrials.gov registry entry for NCT01857895 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exenatide is the first listed.
NCT01857895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01857895 about?
NCT01857895 is a clinical study titled "Feasibility Study of Exenatide by Continuous Subcutaneous Infusion". This is an open-label study to investigate the feasibility of administering exenatide by continuous subcutaneous infusion to healthy subjects. Study will consist of two parts i.e. Part A and B. In Part A 2 healthy subjects will receive exenatide infusion over 24 hours followed by a follow-up visit 1...
What is the current status of trial NCT01857895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-05-16. Estimated completion is 2013-11-01.
What interventions are being tested in trial NCT01857895?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT01857895?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.